Graphite Bio sees its gene editing tech as step above CRISPR

May 26, 2022

While the use of CRISPR is an effective gene editing tool on its own, Dr. Josh Lehrer, CEO of Graphite Bio, contends that the technology doesn’t correct the underlying genetic defect.

CRISPR is the "cut" function and Graphite Bio's technology is the "cut and paste" capability, Lehrer told ScienceBoard.net at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC.

"We have a slightly different approach where what we're trying to do is use CRISPR essentially as more than a pair of scissors. We're trying to build on CRISPR technology to get to very efficient, reproducible, precise cutting and pasting," Lehrer said.

The targeted approach is designed to precisely replace defective genes at their native chromosomal location, allowing for the production of normal gene expression within the inserted cells. Graphite Bio uses a CRISPR system to leverage a natural repair process of cells called homology-directed repair, without introducing any errors.

Watch the video below to learn more.


Lexeo to start phase I/II clinical trial for patients with FA cardiomyopathy
Gene therapy company Lexeo Therapeutics in 2022 plans to launch a phase I/II clinical trial of its adeno-associated virus-based therapy designed to intravenously...
COVID-19 mRNA-based vaccines benefit from decades of research
25 years ago Dr. Drew Weissman, PhD, an infectious disease expert at Penn Medicine, and RNA biologist Kati Kariko, PhD, began their collaboration in...
Genenta Science reports preliminary results of Temferon-glioblastoma study
Biotech company Genenta Science is developing a proprietary hematopoietic stem cell gene therapy, Temferon, for the treatment of a variety of solid tumor...
Next-generation AAV capsids hold key to developing life-changing therapies
Voyager Therapeutics’ discovery platform is identifying novel capsids targeting desired cells and tissues with greater specificity, at lower doses, and...
How to address challenges in producing AAV vectors
There are challenges in producing sufficient quantities of gene therapy products, particularly when it comes to adeno-associated virus (AAV) vectors,...
Atsena Therapeutics’ gene therapy takes aim at childhood blindness
In an interview with ScienceBoard.net, Patrick Ritschel, CEO of Ophthalmology-based gene therapy company Atsena Therapeutics, shared an overview...
Omega Therapeutics looks to tap 'nature's operating system' to control gene expression
Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation,...
Delivery of gene therapies remains a key challenge
Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge,...
Next evolution of CAR T-cell therapy is solid tumors
While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the...

Copyright © 2022 scienceboard.net

Last Updated 5/26/2022 1:49:34 PM